More Alzheimer’s drugs head for FDA review: what scientists are watching

Asher Mullard

Nature, 2021, vol. 599, issue 7886, 544-545

Abstract: Eli Lilly and other pharma firms have begun submitting their anti-amyloid drug hopefuls for approval. But questions linger over the controversial precedent set by Biogen’s aducanumab.

Keywords: Policy; Neurodegeneration; Drug discovery; Alzheimer's disease (search for similar items in EconPapers)
Date: 2021
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/d41586-021-03410-9 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:599:y:2021:i:7886:d:10.1038_d41586-021-03410-9

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-021-03410-9

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().